Position available: Immediately
Length of position: Full time, 2 year-funded position by NIH, California State, Industry
Novel therapeutic approaches to treat viral infections including HIV and COVID-19
Overview: The pandemic COVID-19 emphasized the need to develop novel therapeutic strategies to combat morbidity and mortality from viral infections. The Kelesidis laboratory focuses on novel antioxidants that target increased bioactive lipids and altered mitochondria to attenuate increased systemic inflammation, immune dysfunction and end organ disease in chronic HIV infection. Importantly these antioxidants were also recently shown to attenuate SARS-CoV-2 viral replication and associated inflammatory responses in lung cells. The lab uses in vitro cell culture models, ex vivo models of atherogenesis and gut explants to dissect mechanisms how the cross talk between bioactive lipids, immune, endothelial and epithelial cells drive atherogenesis and how novel therapeutic agents attenuate aberrant proinflammatory cellular pathways. The lab also uses a preclinical humanized mouse model of chronic treated HIV infection to study in vivo how novel therapies attenuate end organ disease. Recent areas of research include studies of pathogenesis of COVID-19 using preclinical in vitro and animal models of SARS-CoV-2 infection.
Responsibilities – Ideal candidates will be expected to:
Contact: To apply, please provide a cover letter and curriculum vitae (with three names of references) to Dr Theodoros Kelesidis at firstname.lastname@example.org